INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF ZYDUS STRATEGIC INVESTMENTS LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **ZYDUS STRATEGIC INVESTMENTS LIMITED** ("the Company"), which comprise the balance sheet as at 31st March 2021, the statement of Profit and Loss and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2021, its loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, no remuneration paid by the Company to its directors during the year.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For **MUKESH M. SHAH & CO.,** Chartered Accountants Firm Registration No.: 106625W

Place: Ahmedabad Date: 26th April, 2021 Udin: 21129675AAAACC8356

Sd/-

Karnik K. Shah Partner Membership No.: 129675

"Annexure A" referred to in the Independent Auditors' Report of even date to the members of ZYDUS STRATEGIC INVESTMENTS LIMITED on the Financial Statements for the year ended 31st March, 2021.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

- 1. The Company does not hold any fixed assets hence clause (i)(a), (i)(b) and (i)(c) of paragraph 3 of the Order are not applicable to the Company for the year under review.
- 2. The Company does not deal in any inventory hence this clause is not applicable to the Company for the year under review.
- 3. The Company has not granted any loan, secured or unsecured, to the companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.
- 4. In our opinion and according to the information and explanations given to us, the Company has not given any loans, guarantees or security or made any investments to which provisions of section 185 and 186 of the Act is applicable, and accordingly paragraph 3 (iv) of the Order is not applicable to the Company.
- 5. The Company has not accepted any deposit from the Public within the meaning of the provisions of section 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder. Further, we are informed that no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any other Court or Tribunal, in this regard.
- 6. In absence of any manufacturing activity carried out by the company, the requirement of maintenance of cost records under sub section 1 of section 148 of the Companies Act, 2013 are not applicable to the Company during the year under audit.
- 7. (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the material statutory dues such as Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Goods and Services tax, Service tax, Custom duty, Excise duty, Value added Tax, cess etc. are not applicable to the company for the year under review. Accordingly, reporting under this clause is not applicable to the company.
 - (b) According to the information and explanations given to us, there is no due under dispute for the Income Tax, Sales Tax, Value added Tax, Excise Duty and Service Tax, GST and other material statutory dues as at 31st March, 2021.
- 8. In our opinion and according to the information and explanations given to us and on the basis of our examination of the books of account, the company has not taken any loans or borrowing from any financial institution, banks, government or there are no amount due to debenture holders during the year, hence, reporting under this clause is not applicable to the company for the year under review.
- 9. The Company did not raise any money by way of initial public offer or further public offer (including debt instruments). The Company has not availed any term loans during the year.
- 10. According to the information and explanations given to us, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- 11. According to the information and explanations given to us and on the basis of our examination of the books of account, no managerial remuneration has been paid or provided by the Company during the year.
- 12. In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable to the Company.

- 13. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- 14. According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- 15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable to the Company.
- 16. In our opinion and according to the information & explanation given to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For **MUKESH M. SHAH & CO.,** Chartered Accountants Firm Registration No.: 106625W

Place: Ahmedabad Date: 26th April, 2021 Udin: 21129675AAAACC8356

Sd/-

Karnik K. Shah Partner Membership No.: 129675

"ANNEXURE B" TO THE AUDITORS' REPORT

Report on the Internal Financial Control clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 ("the act")

We have audited the internal financial controls over financial reporting of **ZYDUS STRATEGIC INVESTMENTS LIMITED** ("the company") as of March 31, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management Responsibility for Internal Financial Controls

The company's management is responsible for establishing and maintaining internal financial control based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India [ICAI]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's Judgement, including the assessment of the material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- 1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- 2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- 3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become

inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For MUKESH M. SHAH & CO.,

Chartered Accountants Firm Registration No.: 106625W

Place: Ahmedabad Date: 26th April, 2021 Udin: 21129675AAAACC8356

Sd/-

Karnik K. Shah Partner Membership No.: 129675

Zydus Strategic Investments Limited Balance Sheet as at March 31, 2021		
Particulars	Note	INR
	No.	As at March 31
		2021
EQUITY AND LIABILITIES:		
Shareholders' Funds:		
Share Capital	3	10,000,0
Reserves and Surplus	4	(204,3
		9,795,6
Current Liabilities:		
Trade Payables due to Other than Micro and Small Enterprises	5	268,4
Total		10,064,0
ASSETS:		
Current Assets:		
Cash and Bank Balances	6	10,059,0
Other Current Assets	7	4,9
Total		10,064,0
Significant Accounting Policies	2	
Notes to the Financial Statements	1 to 14	
As per our report of even date	<u>For a</u>	nd on behalf of the Board
For Mukesh M. Shah & Co.,		
Chartered Accountants		SD/-
Firm Registration Number: 106625W		
·		Nitin D. Parekh
SD/-		Director
		DIN: 00155570
Karnik K. Shah		SD/-
Partner		Harish R. Sadana
Membership Number: 129675		Director
Ahmedabad, Dated: April 26, 2021		DIN: 00026483
	Ahmedat	oad, Dated: April 26, 2021

Zydus Strategic Investments Limited Statement of Profit and Loss for the period ended March 31, 2021			
Particulars	Note	INR	
	No.	Period ended March 31	
		2021	
REVENUE:			
Revenue from Operations	8	66,37	
Total Revenue		66,37	
EXPENSES:			
Other Expenses	9	270,75	
Total Expenses		270,75	
Loss before Tax		(204,37	
Less: Tax Expense:			
Current Tax		-	
Deferred Tax		-	
		-	
Loss for the year		(204,37	
Basic & Diluted Earning per Equity Share [EPS] [in Rupees]	10	(0.4	
Significant Accounting Policies	2		
Notes to the Financial Statements	1 to 14		
As per our report of even date	For	and on behalf of the Board	
For Mukesh M. Shah & Co.,			
Chartered Accountants		SD/-	
Firm Registration Number: 106625W			
		Nitin D. Parekh	
SD/-		Director	
		DIN: 00155570	
Karnik K. Shah		SD/-	
Partner		Harish R. Sadana	
Membership Number: 129675		Director	
Ahmedabad, Dated: April 26, 2021		DIN: 00026483	
	Ahmed	abad, Dated: April 26, 2021	

Note: 1-Company overview:

Zydus Strategic Investments Limited

Zydus Strategic Investments Limited is subsidiary of Cadila Healthcare Limited. The Company is classified as a Core Investment Company [CIC] and is exempt from registration with Reserve Bank of India [RBI]. The registered office of the Company is located at "Zydus Corporate Park", Scheme No.63, Survey No. 536, Khoraj (Gandhinagar) Near Vaishnodevi Circle, S. G. Highway, Ahmedabad -382481.These financial statements were authorised for issue in accordance with a resolution passed by the Board of Directors at their meeting held on April 26, 2021.

Note: 2-Significant Accounting Policies:

1 Basis of Accounting:

The financial statements are prepared under the historical cost convention on the "Accrual Concept" of accountancy in accordance with the accounting principles generally accepted in India and they comply with the Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies [Accounts] Rules, 2014 and other pronouncements issued by the Institute of Chartered Accountants of India [ICAI], to the extent applicable, and with the applicable provisions of the Companies Act, 2013.

2 Use of Estimates:

The preparation of Financial Statements in conformity with the Accounting Standards generally accepted in India requires, the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as at the date of the financial statements and reported amounts of revenues and expenses for the year while actual results could differ from these estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

3 Borrowing Costs:

- A Borrowing costs that are directly attributable to the acquisition/ construction of a qualifying asset are capitalised as part of the cost of such assets, up to the date the assets are ready for their intended use.
- B Other borrowing costs are recognised as an expense in the year in which they are incurred.

4 Investments:

- A Long term and strategic investments are stated at cost, less any diminution in the value other than temporary.
- B Current investments are stated at lower of cost and fair value determined on individual investment basis.
- **C** Investments in shares of foreign subsidiaries and other companies are expressed in Indian currency at the rates of exchange prevailing at the time when the original investments were made.

5 Revenue Recognition:

- A Service income is recognised as per the terms of contracts with the customers when the related services are performed or the agreed milestones are achieved and are net of Goods and service tax, wherever applicable.
- **B** Interest income is recognised on time proportionate method.
- **C** Revenue in respect of other income is recognised when no significant uncertainty as to its determination or realisation exists.

6 Foreign Currency Transactions:

- A The transactions in foreign currencies are stated at the rates of exchange prevailing on the dates of transactions.
- **B** The net gain or loss on account of exchange rate differences either on settlement or on translation of short term monetary items is recognised in the Statement of Profit and Loss.
- **C** Investments in foreign subsidiaries and other companies are recorded in Indian currency at the rates of exchange prevailing at the time when the investments were made.

7 Taxes on Income:

- A Tax expenses comprise of current and deferred tax.
- **B** Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961.
- **C** Deferred tax reflects the impact of current year timing differences between accounting and taxable income and reversal of timing differences of earlier years. Deferred tax is measured based on the tax rates and laws that have been enacted or substantively enacted as of the balance sheet date. Deferred tax assets are recognised only to the extent there is virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised and are reviewed at each balance sheet date.

8 Provisions, Contingent Liabilities and Contingent Assets:

Provision is recognised when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Contingent assets are not recognised in the financial statements. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates.

Zydus Strategic Investments Limited	
Notes to the Financial Statements	
	INR
	As at March 31
	2021
Note: 3-Share Capital:	1
Authorised:	
1,000,000 Equity Shares of Rs.10/- each	10,000,000
	10,000,000
Issued, Subscribed and Paid-up:	
1,000,000 Equity Shares of Rs.10/- each fully paid-up	10,000,000
Total	10,000,000
A The reconciliation in number of choree is as under	
A The reconciliation in number of shares is as under:	
Number of shares at the beginning of the year	-
Add: Issued during the year	1,000,000
Number of shares at the end of the year $P_{\rm end}$. Details of Shareholders holding more than $F_{\rm end}^{(2)}$ of aggregate Equity Shares of $P_{\rm end}$ 10/, each fully poid:	1,000,000
B Details of Shareholders holding more than 5% of aggregate Equity Shares of Rs. 10/- each fully paid:	
Cadila Healthcare Limited- Holding Company	000.000
Number of Shares	900,000
% to total share holding	90%
Zydus Healthcare Limited	100.000
Number of Shares	100,000
% to total share holding	10%
C The Company has only one class of equity shares having a par value of Rs. 10/- per share. Each holder of	
equity share is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to	
the approval of the shareholders in the Annual General Meeting, except in the case of interim dividend. In the	
event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their	Ĭ
holding in the assets remaining after distribution of all preferential amounts.	
Note: 4-Reserves and Surplus:	
Surplus in Statement of Profit and Loss:	
Balance as per last Balance Sheet	_
Add: Loss for the year	(204,376)
Balance as at the end of the year	(204,376)
Total	(204,376)
	()
Note: 5-Trade Payables:	
Micro and Small Enterprises (*)	-
Others	268,451
Total	268,451
(*)During the year there is no transaction with Micro and Small Enterprises neither there is any balance	
or interest payable. Hence the detailed disclosure for Micro and Small Enterprises is not given.	
Note:6-Cash and Bank Balances:	
Balances with Banks	10,059,096
Total	10,059,096
Note:7-Other Current Assets:	
Advance Payment of Tax	4,979
Total	4,979

		INR
		Period ended March 31
		2021
te: 8-Revenue from Operations:		
Finance Income:		(()
Interest Income Total		<u> </u>
		00,3
te: 9-Other Expenses:		10.0
Payment To Statutory Auditors (*) Preliminary Expenses		10,0
Registration Fees (Roc)		207,2
Application / Filing Fees		2,3
Stamp Duty Expenses		50,1
Other Expenses		1,1
		270,7
(*) Payment to the Statutory Auditors [excluding GST]:		10.0
i - As Auditor		10,0
 For Other Services Total 		10,0
- 10(2)		10,0
e: 10-Calculation of Earnings per Equity Share [EPS]:		
The numerators and denominators used to calculate the basic and	diluted EPS are as follows:	
A Profit attributable to Shareholders	INR	(204,3
B Weighted average number of Equity shares outstandin	g during the year Numbers	498,6
C Nominal value of equity share	INR	
D Basic and adjusted EPS	INR	(0.
D Basic and adjusted EPS	INR	(0.
e: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Pa		
e: 11-Related Party Transactions:		
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Pa a Holding Company Cadila Healthcare Limited		
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Pa a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities	arty Relationship with whom transactions ha	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Pa a Holding Company Cadila Healthcare Limited		
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Pa a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited	arty Relationship with whom transactions ha Zydus International Private Limited [Ireland]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Parties a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited	arty Relationship with whom transactions ha Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Parties a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited	Try Relationship with whom transactions ha Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Parties a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Parties a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Parties a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA]	
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA]	
Image: Sec: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA]	
Image: Sec: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA]	ve taken place:
Ite: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Dialforhealth Greencross Limited Zydus Pharmaceuticals Limited Violio Healthcare Limited Zydus VTEC Limited	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa]	ive taken place:
Ite: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Liva Nutritions Limited Liva Investment Limited Dialforhealth Greencross Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Dialforhealth Greencross Limited Zydus VTEC Limited Zydus VTEC Limited Zydus Foundation	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals LLC [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa]	ive taken place:
Ite: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Liva Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Dialforhealth Greencross Limited Dialforhealth Greencross Limited Violio Healthcare Limited Biochem Pharmaceuticals Limited Biochem Pharmaceuticals Limited Zydus VTEC Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments,	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa Script Management Services (Pty) Ltd [South A Zydus France, SAS [France]	ive taken place:
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa Script Management Services (Pty) Ltd [South A Zydus France, SAS [France] Laboratorios Combix S.L. [Spain]	ive taken place:
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Alidac Healthcare (Myanmar) Limited [Myanmar]	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) Inc. [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa Script Management Services (Pty) Ltd [South A Zydus France, SAS [France] Laboratorios Combix S.L. [Spain] Etna Biotech S.R.L. [Italy]	ive taken place:
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Nutritions Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceuticals Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Alidac Healthcare (Myanmar) Limited [Myanmar] Zydus Healthcare Philippines Inc. [Philippines]	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) Inc. [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa Script Management Services (Pty) Ltd [South Africa Zydus France, SAS [France] Laboratorios Combix S.L. [Spain] Etna Biotech S.R.L. [Italy] Zydus Nikkho Farmaceutica Ltda. [Brazil]	a] Africa]
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceuticals Limited Zydus VTEC Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Alidac Healthcare (Myanmar) Limited [Myanmar] Zydus Lanka (Private) Limited [Sri Lanka]	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) Inc. [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa Script Management Services (Pty) Ltd [South Africa Zydus France, SAS [France] Laboratorios Combix S.L. [Spain] Etna Biotech S.R.L. [Italy] Zydus Nikkho Farmaceutica Ltda. [Brazil] Zydus Pharmaceuticals Mexico SA De CV [Mex	ve taken place:
te: 11-Related Party Transactions: Name of the Related Parties and Nature of the Related Para a Holding Company Cadila Healthcare Limited b Fellow Subsidiary Companies/entities Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Nutritions Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceuticals Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Alidac Healthcare (Myanmar) Limited [Myanmar] Zydus Healthcare Philippines Inc. [Philippines]	Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) Inc. [USA] ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA] Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Therapeutics Inc. [USA] Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa Script Management Services (Pty) Ltd [South Africa Zydus France, SAS [France] Laboratorios Combix S.L. [Spain] Etna Biotech S.R.L. [Italy] Zydus Nikkho Farmaceutica Ltda. [Brazil]	ve taken place:

	Zydus Strategic Investments Limited Notes to the Financial Statements		
lote: 11-Related Party Transactions: Continue			
c Directors:	· · · ·		
Nitin D. Parekh	Director		
Harish R. Sadana	Director		
Vishal J Gor	Director		
B Transactions with Related Parties:			
	the related parties in the ordinary course of business	and at arm's leng	th terms:
a Details relating to parties referred to in N	lote 9-A [a & b]	Value of the Tra	ansactions [INR]
	Holdin		ellow Subsidiary Company
Nature of Transactions			ed March 31
Nature of Hansactions		20	
Reimbursement of Expenses:			
Cadila Healthcare Limited		257,351	
Investments:			
Issue of Share Capital:			
Cadila Healthcare Limited		9,000,000	
Zydus Healthcare Limited			1,000,00
Total		9,000,000	1,000,000
Outstanding as at March 21, 20	21.		
Outstanding as at March 31, 202	21:		
Payable:		057.054	
Cadila Healthcare Limited		257,351	
b There are no transaction to parties referre	ed to in Note 9-A [c]		
lote: 12 The Company has losses under tax laws during	ed to in Note 9-A [c] the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence		
lote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen	the year, resulting in to deferred tax assets. However,		
lote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- lote: 13	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence	ce that are sufficien	nt.
lote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- lote: 13	the year, resulting in to deferred tax assets. However,	ce that are sufficien	nt.
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f	ce that are sufficien	nt. s.
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various	ce that are sufficien	nt. s. re restrictions on
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f	ce that are sufficien	nt. s. re restrictions on
lote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- lote: 13 Company has been incorporated on July 10, 202 lote: 14 In financial year 2020-21, Covid-19 the global p	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various	ce that are sufficien	nt. s. re restrictions on
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business.	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various	rinancial statement s sectors with seven s that there is no m	nt. s. re restrictions on naterial impact on
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business.	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co.,	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts on behalf of the Board
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts on behalf of the Board
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on haterial impact on nts on behalf of the Board SD/-
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant and As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts on behalf of the Board SD/- Nitin D. Parekh
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant and As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W SD/-	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts on behalf of the Board SD/- Nitin D. Parekh Director DIN: 00155570
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W SD/- Karnik K. Shah	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on haterial impact on nts on behalf of the Board SD/- Nitin D. Parekh Director DIN: 00155570 SD/-
Iote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Iote: 13 Company has been incorporated on July 10, 202 Iote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W SD/- Karnik K. Shah Partner	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on naterial impact on nts on behalf of the Board SD/- Nitin D. Parekh Director DIN: 00155570 SD/- Harish R. Sadana
Jote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Jote: 13 Company has been incorporated on July 10, 202 Jote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W SD/- Karnik K. Shah Partner Membership Number: 129675	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	inancial statement s sectors with seven that there is no m	nt. s. re restrictions on haterial impact on nts on behalf of the Board SD/- Nitin D. Parekh Director DIN: 00155570 SD/-
Jote: 12 The Company has losses under tax laws during deferred tax assets are not recognised in absen- Jote: 13 Company has been incorporated on July 10, 202 Jote: 14 In financial year 2020-21, Covid-19 the global p movement of people and goods. As per the curr its business. Signatures to Significant As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W SD/- Karnik K. Shah Partner	the year, resulting in to deferred tax assets. However, ce of virtual certainty supported by convincing evidence 20. Hence previous years figures are not disclosed in f pandemic continue to impact operations across various rent assessment of the situation the Company believes	rinancial statement s sectors with seven s that there is no m mancial Statemen For and	nt. s. re restrictions on naterial impact on nts on behalf of the Board SD/- Nitin D. Parekh Director DIN: 00155570 SD/- Harish R. Sadana